Hedge funds cut NFLX, keep big bets on MSFT, AMZN, add NVDA
Investing.com - Guggenheim raised its price target on Cidara Therapeutics (NASDAQ:CDTX) stock to $70.00 from $69.00 on Friday, while maintaining a Buy rating following the company’s second-quarter 2025 earnings release. The $1.37 billion market cap company has seen its stock surge over 430% in the past year, currently trading at $61.73. According to InvestingPro data, the company holds more cash than debt on its balance sheet, though analysts don’t expect profitability this year.
The research firm highlighted that Cidara’s discussions with the FDA remain on track, with an end-of-Phase 2 meeting scheduled for later this month. Management does not anticipate substantial differences in design or discussion from its Type C meeting held in May, with more details expected after receipt of minutes in September. InvestingPro analysis reveals the company maintains strong liquidity with a current ratio of 3.87, suggesting solid operational flexibility for its development programs.
Guggenheim noted that Cidara is operationally prepared for either a Southern Hemisphere or earlier fall 2025 Northern Hemisphere start in September, with doses manufactured and Northern Hemisphere sites prepared. The company’s formulation development continues with the goal of having a higher concentration, single-use vial at launch.
The firm also pointed out that Cidara’s discussions with BARDA remain on track, with potential base period funding focused on on-shoring manufacturing and more substantial potential option period funding directed toward further clinical program expansion.
Additional data from Cidara’s Phase 2b trial will be shared at upcoming conferences, including the ISRV (September 17-20) and ESWI (October 20-23), with Guggenheim focusing on the PK/PD analysis at ESWI. Analyst consensus remains bullish, with price targets ranging from $53 to $115. For deeper insights into Cidara’s financial health and growth prospects, access the comprehensive Pro Research Report available on InvestingPro, which covers over 1,400 US stocks with expert analysis and actionable intelligence.
In other recent news, Sidera Therapeutics has announced its Q2 2025 earnings, highlighting significant progress in its product pipeline and strategic initiatives. Although the company is not currently generating revenue, it maintains a strong financial position with over $500 million in cash. This financial strength has been bolstered by a recent public offering. These developments indicate a positive outlook for the company’s ongoing projects. Despite the lack of revenue, the market has shown positive sentiment towards Sidera’s advancements. The company’s strategic focus on innovation continues to attract attention in the industry. Investors are keenly observing how Sidera leverages its financial resources for future growth.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.